Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
57.23
+0.32 (+0.56%)
Streaming Delayed Price
Updated: 1:10 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
...
24
25
26
27
28
29
30
31
Next >
Regeneron Could Have a Big Catalyst Coming in 2022
October 09, 2021
Cancer drug Libtayo could receive FDA approval for its fourth indication in January.
Via
The Motley Fool
Exposures
Product Safety
Will Chart Analysts Notice Bad Omen on Sanofi's Chart
October 08, 2021
If history is any guide, there may be trouble ahead for shares of Sanofi(NASDAQ:SNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program
October 07, 2021
Denali Therapeutics Inc (NASDAQ: DNLI) announced data from the Phase 1 trial evaluating DNL343, eIF2B activator, in 95 healthy volunteers. DNL343 was generally...
Via
Benzinga
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
October 06, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 6, 2021 – USA News Group – As vaccine passport programs continue to roll out in new markets across the globe, especially in...
Via
FinancialNewsMedia
Exposures
COVID-19
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
October 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...
Via
Benzinga
Multiple Bits Of Bad News
September 28, 2021
Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser.
Via
Talk Markets
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...
Via
Benzinga
Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know
September 28, 2021
Sanofi SA (NASDAQ: SNY) is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported. Sanofi...
Via
Benzinga
Exposures
COVID-19
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
September 27, 2021
Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Mond...
Via
Benzinga
Exposures
COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
September 27, 2021
Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ:
Via
Benzinga
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is...
Via
Benzinga
Pfizer Nabs Booster OK In U.S. — But How Long Will It Hold The Covid Lead?
September 23, 2021
The FDA allowed the Pfizer-BioNTech Covid booster for some. But rivals are coming.
Via
Investor's Business Daily
Exposures
Product Safety
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
September 20, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. ...
Via
Benzinga
AbbVie's Pain Is Sanofi's and Regeneron's Gain
September 18, 2021
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.
Via
The Motley Fool
Exposures
Product Safety
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
September 12, 2021
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest...
Via
Benzinga
Exposures
COVID-19
Product Safety
Week In Review: Sanofi Acquires Kadmon, A US-China Pharma, For $1.9 Billion
September 11, 2021
France's Sanofi will acquire Kadmon Holdings of New York City in a $1.9 billion deal. In 2019, Kadmon formed a JV with BioNova Pharma to develop its novel lead drug, Rezurock (belumosudil) in China.
Via
Talk Markets
Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?
September 11, 2021
Pfizer's abrocitinib faces some challenges despite encouraging late-stage results for the drug in treating eczema.
Via
The Motley Fool
EMA Gives Nod To Additional Sites For Pfizer - BioNTech COVID-19 Vaccine
September 09, 2021
European Medical Agency (EMA) has approved additional manufacturing sites to produce Comirnaty, the COVID-19 vaccine developed by Pfizer Inc (NYSE: PFE) and...
Via
Benzinga
Exposures
COVID-19
Sanofi's BTK Inhibitor Disappoints In Phase 3 Autoimmune Disease Trial
September 09, 2021
Sanofi SA's (NASDAQ: SNY) BTK inhibitor, rilzabrutinib, has flunked its first major clinical test. Rilzabrutinib was Principia Biopharma Inc's one of the...
Via
Benzinga
KDMN Stock: 6 Things to Know About Biopharma Kadmon Holdings as Shares Skyrocket
September 08, 2021
Kadmon Holdings (KDMN) stock is rising higher on Wednesday following news of a deal with Sanofi (SNY) that comes to $1.9 billion.
Via
InvestorPlace
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...
Via
Benzinga
Exposures
COVID-19
Kadmon Stock Hits 5-Year High On Sanofi's $1.9 Billion Takeover
September 08, 2021
Sanofi said Wednesday it will spend $1.9 billion to acquire small biotech Kadmon Holdings, and KDMN stock rocketed to a five-year high.
Via
Investor's Business Daily
Why Kadmon Holdings Stock Is Rocketing Higher Today
September 08, 2021
Sanofi adds another bolt-on acquisition in what is turning out to be a busy year for the French pharma titan.
Via
The Motley Fool
Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know
September 08, 2021
Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August 31, 2021
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New...
Via
Benzinga
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
August 31, 2021
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The...
Via
Benzinga
Exposures
COVID-19
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
August 30, 2021
Pfizer Inc (NYSE: PFE) announced topline data from the JADE DARE Phase 3 trial comparing abrocitinib with Sanofi SA (NASDAQ: SNY) - Regeneron...
Via
Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
August 30, 2021
A Phase 3 trial evaluating Dupixent (dupilumab) for treating children aged 6 months to 5 years with moderate-to-severe atopic dermatitis met its primary and secondary...
Via
Benzinga
< Previous
1
2
...
24
25
26
27
28
29
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.